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Mitochondrial cytopathies are clinically and biochemically heterogeneous 
disorders affecting energy production. Because of the heterogeneity of disorders, 
the large number of biochemical and genetic defects, and wide spectrum of 
clinical course, there are limited data about proven effective therapies. Overall, 
treatments for mitochondrial cytopathies are intended to augment energy 
production and reduce the production of free radicals and other toxic metabolites 
that further limit the generation of cellular energy. Treatment can be aimed at 
increasing respiratory chain activity by supplementing relative deficiencies of 
cofactors required for proper functioning. Possible strategies to consider may 
include dietary management, supplemental vitamins and cofactors, and specific 
medications aimed at a particular symptom.
The clinical benefits for cofactor and vitamin therapy can include improved 
strength and endurance, although patients report a variety of benefits. Coenzyme 
Q10 can be given at dosages ranging from 5 to15 mg/kg/d in two to three 
divided doses. Levocarnitine is advocated at dosages of 30 mg/kg/d in two to 
three divided doses. Riboflavin (vitamin B2) at dosages of 100 to 400 mg/d 
has been shown to be beneficial in some patients. The use of creatine has been 
shown to improve strength in patients with mitochondrial myopathies, although 
its long-term use should be consider with caution Because of the potential for 
renal toxicity. The use of antioxidants .(<-lipoic acid, vitamin E, vitamin C, 
®-carotene, selenium, vitamin K and N-acetylcysteine) to lessen free radical 
damage to the mitochondrial membrane has a scientific rationale, but again 
proof of effectiveness does not exist. 
The other B vitamins have been used, with reports of effectiveness in small numbers 
of patients, likely those with a rare but specific vitamin-responsive syndrome. 
Treatment with Dichloroacetate associate with some degree of improvement in 
several studies. Its primary site of action is the pyruvate dehydrogenase (PDH) 
complex, which it stimulates by altering its phosphorylation state and stability.
In critical situations, when lactic acid and ammonia levels are extremely 
elevated, the use of continuous infusion insulin (0.05-0.1 U/kg/h), using very 
frequent glucose monitoring, may help reverse catabolism, decrease circulating
toxic free fatty acids, and lower lactic acid and ammonia levels. The use of 
sodium benzoate, phenylbutyrate, and sodium phenylacetate can bind conjugate 
ammonia in the case of severe hyperammonemia. Enteral use of lactulose also 
can help lower ammonia levels. 
Dietary management for mitochondrial disorders remains largely trial and error. 
A low-carbohydrate, high fat diet is helpful for some patients with complex I 
deficiency but others do better on a high-carbohydrate, low-fat diet. Patients 
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with PDH deficiency should be treated with a ketogenic 
diet. 
The use of frequent, small-volume feedings is generally 
well tolerated. For children with primary and secondary 
gluconeogenetic defects, avoidance of fasting is 
recommended.
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